MAJOR UNIVERSITY LICENSING
AND RESEARCH AGREEMENT
WITH POTENTIAL TO SAVE
MILLIONS OF LIVES
Deal with Douglas Pharmaceuticals to develop
new cervical cancer therapy
UMIP HIGHLIGHTS
The University, though UMI
3
Ltd, has signed
a licensing and research agreement with
Douglas Pharmaceuticals that could save the
lives of millions of women around the world
suffering from early stage cervical cancer.
The deal initially sees New Zealand-based
Douglas Pharmaceuticals sponsor research
at the University to develop the cervical
cancer treatment further. Then Douglas
will manufacture the therapy and drive
further development, clinical trials and
commercialisation on an international basis,
focusing initially on a multi-centre phase 2
clinical trial in the UK.
Douglas is a family owned company
headquartered in Auckland, New Zealand
which is committed to improving health
outcomes through price containment and
accessibility to complex generic medicines
developed in-house for international markets.
A burgeoning interest in drug repurposing is
evidenced in the current collaboration with
the University.
Douglas Managing Director, Jeff Douglas,
said: "We are delighted in the collaboration
with the University, in this promising
treatment of early stage cervical cancer. We
are confident in the research team which
consists of Drs Ian and Lynne Hampson and
Dr Pierre-Martin Hirsch, who is President
Elect of the British Society of Colposcopy
and Cervical Pathology and we look forward
to progressing the Phase 2 trial with them."
